Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AbCellera Biologics Inc. Director's Dealing 2021

Dec 10, 2021

31942_dirs_2021-12-10_87f1d635-8e2e-4f89-abaf-a092ef0bf09e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AbCellera Biologics Inc. (ABCL)
CIK: 0001703057
Period of Report: 2021-12-07

Reporting Person: Montalbano John S. (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-08-27 Share option (right to buy) $17.58 A 34282 Acquired 2031-08-27 Common Shares (34282) Direct
2021-12-07 Share option (right to buy) $14.55 A 45532 Acquired 2031-12-07 Common Shares (45532) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Shares 26000 Direct
Common Shares 5000 Indirect